3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
20
Phase 1/2
11
Phase 3
8
Phase 1
6
Phase NA
1
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Triple Negative Breast Neoplasms
7
Breast Neoplasms
6
Lung Neoplasms
5
Ovarian Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Neoplasms
2
Medulloblastoma
2
Fallopian Tube Neoplasms
2
Brain Neoplasms
2
Waldenstrom Macroglobulinemia
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Thymic epithelial tumor
1
Thrombocythemia, Essential
1
Stage IIIB or IV Non-Small Cell Lung Cancer
1
Squamous NSCLC
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Retinoblastoma
1
Recurrence
1
Primary Myelofibrosis
1
Primary Malignant Neoplasm of Ovary
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Interventions
Temozolomide
3
Gemcitabine
3
Etoposide
3
pembrolizumab
2
Rituximab
2
Lomustine
2
Haloperidol
2
Dexamethasone
2
Cyclosporine
2
vocimagene amiretrorepvec
1
trofosfamide
1
tinostamustine
1
selinexor
1
ruxolitinib
1
regorafenib
1
peginterferon alfa-2b
1
osimertinib
1
menatetrenone
1
interferon gamma-1b
1
interferon gamma, Cys(-3), Tyr(-2), Cys(-1)-
1
imetelstat
1
glumetinib
1
fludarabine
1
etoposide phosphate
1
eculizumab
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
carbon-11 acetate
1
blinatumomab
1
auricularum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Recurrence
×
Carboplatin
×
Clear all
NCT00749723
2018-07-20
HIT-REZ-2005
University Hospital, Bonn
Phase 2/3
Completed
174 enrolled